My watch list  

Paromomycin sulfate

Paromomycin sulfate
Systematic (IUPAC) name
CAS number 1263-89-4
ATC code A07AA06
PubChem 165580
DrugBank ?
Chemical data
Formula C23H47N5O18S 
Mol. mass 615.629 g/mol
Pharmacokinetic data
Bioavailability None
Metabolism None
Half life  ?
Excretion Fecal
Therapeutic considerations
Pregnancy cat.


Legal status

Schedule VI U.S.

Routes Oral, intramuscular

Paromomycin sulfate (brand name Humatin) is a drug that fights intestinal infections such as cryptosporidiosis and amoeba infection, or amoebiasis and was developed as a therapeutic against visceral leishmaniasis by the Institute for OneWorld Health. Paromomycin was granted orphan drug status in 2005[1] and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis.[2]

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.[3]


  1. ^ Institute for OneWorld Health (23 May 2005). "Institute for OneWorld Health Drug Receives “Orphan” Designation From U.S. and European Regulatory Agencies". Press release. Retrieved on 2007-02-10.
  2. ^ Institute for OneWorld Health (8 September 2006). "New cure for deadly visceral leishmaniasis (kala-azar) approved by government of India". Press release. Retrieved on 2007-02-10.
  3. ^ Vicens, Quentin; Eric Westhof (August 2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure 9 (8): 647–658. doi:10.1016/S0969-2126(01)00629-3. PMID 11587639. Retrieved on 2007-02-10.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Paromomycin_sulfate". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE